Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St Jude plans $500m share repurchase

This article was originally published in Clinica

Executive Summary

St Jude Medical has announced plans for a $500m share buy-back programme. The repurchases will be carried out through various transactions in both the public and private financing markets. The repurchased shares will be available for general corporate purposes, including offsetting dilution and other equity-based employee benefit plans. St Paul, Minnesota-based St Jude had around 330 million shares of common stock outstanding as of 1 August.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT097729

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel